Last reviewed · How we verify
ketorolac 0.5%
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and thereby decrease inflammation and pain.
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and thereby decrease inflammation and pain. Used for Ocular inflammation and pain following ophthalmic surgery, Allergic conjunctivitis.
At a glance
| Generic name | ketorolac 0.5% |
|---|---|
| Also known as | Acular, ketorolac tromethamine, Apo-Ketorolac |
| Sponsor | Queen's University |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Ketorolac blocks both COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. By reducing prostaglandin levels, ketorolac provides analgesic and anti-inflammatory effects. The 0.5% ophthalmic formulation is used topically on the eye to reduce ocular inflammation and pain.
Approved indications
- Ocular inflammation and pain following ophthalmic surgery
- Allergic conjunctivitis
Common side effects
- Ocular irritation or stinging
- Conjunctival erythema
- Headache
- Corneal erosion or ulceration (with prolonged use)
Key clinical trials
- Comparison of Pain Reduction in Painful Chronic Wounds With and Without Fat Grafting (NA)
- Rectal Indomethacin vs Intravenous Ketorolac (PHASE4)
- NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis (PHASE3)
- Opioid-Free Pain Protocol After Shoulder Arthroplasty (PHASE4)
- Intranasal Ketorolac Trial (PHASE2)
- Comparison of Intranasal Ketorolac and Intranasal Ketamine in Digital Nerve Block Pain (PHASE3)
- The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery) (PHASE4)
- Comparing Intramuscular Fentanyl and Ketorolac With Nerve of Arnold (NOA) Block for Bilateral Myringotomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ketorolac 0.5% CI brief — competitive landscape report
- ketorolac 0.5% updates RSS · CI watch RSS
- Queen's University portfolio CI